Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2250492/are-you-a-growth-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_growth_score-2250492
Apr 04, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
GSK (GSK) Registers a Bigger Fall Than the Market: Important Facts to Note
https://www.zacks.com/stock/news/2249459/gsk-gsk-registers-a-bigger-fall-than-the-market-important-facts-to-note?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2249459
Apr 02, 2024 - GSK (GSK) concluded the recent trading session at $41.79, signifying a -1.49% move from its prior day's close.
0
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2248353/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2248353
Apr 01, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
Here's Why GSK (GSK) Gained But Lagged the Market Today
https://www.zacks.com/stock/news/2247009/here-s-why-gsk-gsk-gained-but-lagged-the-market-today?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2247009
Mar 27, 2024 - GSK (GSK) closed at $42.99 in the latest trading session, marking a +0.47% move from the prior day.
0
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2246577/aeterna-zentaris-aezs-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2246577
Mar 27, 2024 - AEterna Zentaris (AEZS) delivered earnings and revenue surprises of -19.59% and 2,925%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
GSK (GSK) Stock Moves -0.09%: What You Should Know
https://www.zacks.com/stock/news/2246352/gsk-gsk-stock-moves-0-09-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2246352
Mar 26, 2024 - GSK (GSK) closed at $42.79 in the latest trading session, marking a -0.09% move from the prior day.
0
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2245649/equillium-inc-eq-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2245649
Mar 25, 2024 - Equillium (EQ) delivered earnings and revenue surprises of 58.82% and 4.08%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
GSK or TECH: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2245610/gsk-or-tech-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2245610
Mar 25, 2024 - GSK vs. TECH: Which Stock Is the Better Value Option?
0
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
https://www.zacks.com/stock/news/2244405/gsk-follows-rivals-to-cap-out-of-pocket-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244405
Mar 21, 2024 - GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.
0
GSK Outperforms Industry on Strength in Key Drugs & Vaccines
https://www.zacks.com/stock/news/2243568/gsk-outperforms-industry-on-strength-in-key-drugs-vaccines?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2243568
Mar 20, 2024 - Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.
0